Distinguished in Anemia

Dr. John Glaspy

Hematology | Oncology
The Regents Of The University Of California
3701 Skypark Dr, Suite 200, 
Torrance, CA 
Offers Telehealth
Distinguished in Anemia
The Regents Of The University Of California
3701 Skypark Dr, Suite 200, 
Torrance, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Glaspy is a Hematologist and an Oncologist in Torrance, California. Dr. Glaspy is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Breast Cancer, Melanoma, Angiosarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 35 articles in the study of Anemia.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
3701 Skypark Dr, Suite 200, Torrance, CA 90505

Additional Areas of Focus

Dr. Glaspy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: June 20, 2024
Intervention Type: Biological, Drug
Study Drugs: LHC165, PDR001
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Drug
Study Drugs: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Study Phase: Phase 3
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted
Enrollment Status: Terminated
Publish Date: August 15, 2023
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab, Talimogene Laherparepvec
Study Phase: Phase 1
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Drugs: FG-3019, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: June 10, 2022
Intervention Type: Biological, Drug
Study Drugs: CC-486, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 8 Less Clinical Trials

99 Total Publications

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.
Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 29, 2025
Similar Doctors
Distinguished in Anemia
Dr. Caroline I. Piatek
Hematology | Oncology
Distinguished in Anemia
Dr. Caroline I. Piatek
Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (19.3 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Caroline Piatek is a Hematologist and an Oncologist in Los Angeles, California. Dr. Piatek is rated as an Elite provider by MediFind in the treatment of Anemia. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Splenectomy, and Bone Marrow Aspiration.

Distinguished in Anemia
Dr. Shahrooz Eshaghian
Oncology | Hematology
Distinguished in Anemia
Dr. Shahrooz Eshaghian
Oncology | Hematology
2080 Century Park East, Suite 1005, 
Los Angeles, CA 
 (17.4 miles away)
310-229-3555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shahrooz Eshaghian is a Hematologist and an Oncologist in Los Angeles, California. Dr. Eshaghian is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Multiple Myeloma, Bone Tumor, Deep Vein Thrombosis, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Eshaghian is currently accepting new patients.

Distinguished in Anemia
Dr. Raymundo Romero
Oncology | Hematology
Distinguished in Anemia
Dr. Raymundo Romero
Oncology | Hematology

Hao Wei Zhang MD Inc

1700 E Cesar E Chavez Ave, Suite 2600, 
Los Angeles, CA 
 (18.2 miles away)
323-264-7238
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raymundo Romero is an Oncologist and a Hematologist in Los Angeles, California. Dr. Romero is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Plasmacytoma, Anemia, Inflammatory Breast Cancer, and Thrombocytopenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glaspy's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 98 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile